Investor Overview

Webcast ImageWebcast
AtriCure, Inc. at Canaccord Genuity Growth Conference (Live)
08/10/16 at 1:30 p.m. ET
Webcast ImageWebcast
Q2 2016 AtriCure, Inc. Earnings Conference Call (Live)
08/04/16 at 4:30 p.m. ET

Corporate Profile

AtriCure is a medical device company providing innovative solutions designed to decrease the global Afib epidemic.

Stock Quote

ATRC (Common)
PriceChange% ChangeVolume
$15.19 + 0.473.19%422,531
Previous CloseToday's OpenIntraday HighIntraday Low
$14.72$14.72$15.31$14.53
Exchange: NASDAQ (US Dollar)
07/29/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Featured Reports

Date
05/06/16
Download Documentation Investor Presentation
04/28/16
Download Documentation  Q1 2016 Earnings Call Transcript
04/18/16
Download Documentation 2015 Annual Report
03/24/15
Download Documentation AtriCure Analyst Day Presentation

All Recent News

DateTitle 
07/22/16AtriCure to Present at the Canaccord Genuity Growth Conference
MASON, Ohio--(BUSINESS WIRE)--Jul. 22, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Canaccord Genuity Growth Conference at the Intercontinental Hotel in Boston on Wednesday, August 10, 2016. Management is scheduled to present at 1:30 p.m. Eastern Time. A live audio webcast of the presentation may be accessed by visit... 
Printer Friendly Version
07/11/16AtriCure to Announce Second Quarter 2016 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Jul. 11, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the second quarter of 2016 on Thursday, August 4, 2016. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, August 4, 2016 to discuss its second quarter 2016 financial results. A live webcast of the c... 
Printer Friendly Version
06/29/16AtriCure Receives CE Mark for the AtriClip® PRO2 Device
CE Mark brings the increased functionality of the AtriClip PRO2 device to the European market for use in managing the left atrial appendage; product was launched in the U.S. in April 2016 MASON, Ohio--(BUSINESS WIRE)--Jun. 29, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has received CE Mark for the AtriClip PRO2 Left ... 
Printer Friendly Version
06/21/16AtriCure Announces the First Patient Enrolled in the FROST Cryoanalgesia Study
FROST will evaluate cryoablation of peripheral nerves for the temporary management of post-operative pain MASON, Ohio--(BUSINESS WIRE)--Jun. 21, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced the first patient has been enrolled in the FROST study at William Beaumont Hospital, Dearborn, MI. This company-sponsored trial ... 
Printer Friendly Version
  More News >>

National Recent News

DateTitle 
07/22/16AtriCure to Present at the Canaccord Genuity Growth Conference
MASON, Ohio--(BUSINESS WIRE)--Jul. 22, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Canaccord Genuity Growth Conference at the Intercontinental Hotel in Boston on Wednesday, August 10, 2016. Management is scheduled to present at 1:30 p.m. Eastern Time. A live audio webcast of the presentation may be accessed by visit... 
Printer Friendly Version
07/11/16AtriCure to Announce Second Quarter 2016 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Jul. 11, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the second quarter of 2016 on Thursday, August 4, 2016. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, August 4, 2016 to discuss its second quarter 2016 financial results. A live webcast of the c... 
Printer Friendly Version
06/21/16AtriCure Announces the First Patient Enrolled in the FROST Cryoanalgesia Study
FROST will evaluate cryoablation of peripheral nerves for the temporary management of post-operative pain MASON, Ohio--(BUSINESS WIRE)--Jun. 21, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced the first patient has been enrolled in the FROST study at William Beaumont Hospital, Dearborn, MI. This company-sponsored trial ... 
Printer Friendly Version
05/02/16AtriCure to Present at the UBS Global Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--May 2, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the UBS Global Healthcare Conference at the Grand Hyatt in New York on Monday, May 23, 2016. Management is scheduled to present at 11:00 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors p... 
Printer Friendly Version
  More National News >>

International Recent News

DateTitle 
06/29/16AtriCure Receives CE Mark for the AtriClip® PRO2 Device
CE Mark brings the increased functionality of the AtriClip PRO2 device to the European market for use in managing the left atrial appendage; product was launched in the U.S. in April 2016 MASON, Ohio--(BUSINESS WIRE)--Jun. 29, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has received CE Mark for the AtriClip PRO2 Left ... 
Printer Friendly Version
01/19/16AtriCure Announces Approval for the AtriClip in Japan
Approval opens up a new market for the most widely implanted left atrial appendage occlusion device in the world WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 19, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for its AtriClip™ product... 
Printer Friendly Version
10/01/13In the Fight Against Atrial Fibrillation, AtriCure Launches Maze IV Training Program in Europe
AMSTERDAM, Netherlands--(BUSINESS WIRE)--Oct. 1, 2013-- AtriCure, Inc. (Nasdaq: ATRC), is partnering with leading atrial fibrillation (Afib) centers and thought leaders across Europe to provide best-in-class training on surgical ablation. The launch of an international Maze IV Training program will take place on October 1 in Germany at Sana Stuttgart Cardiac Surgery Center, one of six initial European hospitals selected to participate in th... 
Printer Friendly Version
06/18/13Promising Mid-Term Results From Thoracoscopic Ablation of Persistent Atrial Fibrillation Presented at Meeting of International Society for Minimally Invasive Cardiothoracic Surgery
Patients show three-year freedom from atrial fibrillation, anti-arrhythmic drugs PRAGUE--(BUSINESS WIRE)--Jun. 18, 2013-- A leading German cardiovascular heart center reported promising mid-term results for the surgical treatment of persistent atrial fibrillation (Afib) during last week’s International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) meeting being held in Prague, Czech Republic. At three-year follow-up, 80 percen... 
Printer Friendly Version
  More International News >>

Company Calendar

DateTitle
08/04/16 
4:30 p.m. ET
Q2 2016 AtriCure, Inc. Earnings Conference Call
08/10/16 
1:30 p.m. ET
AtriCure, Inc. at Canaccord Genuity Growth Conference
  More Events >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.